Use of 2 anti-SPARC antibodies to predict response to chemotherapy for pancreatic adenocarcinoma

  • US 9,091,697 B2
  • Filed: 02/25/2013
  • Issued: 07/28/2015
  • Est. Priority Date: 05/28/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a pancreatic adenocarcinoma in an animal with a chemotherapeutic regimen comprising paclitaxel and gemcitabine, wherein said method comprises:

  • (a) obtaining histologic sections from a tumor resulting from the pancreatic adenocarcinoma,(b) applying a first anti-SPARC antibody to a first histologic section of the tumor, wherein the first anti-SPARC antibody preferentially immunostains SPARC in tumor cells and wherein the first anti-SPARC antibody recognizes a SPARC epitope recognized by monoclonal antibody MAB941;

    (c) applying a second anti-SPARC antibody to the first histologic section of (a) or a second histologic section of the tumor, wherein the second anti-SPARC antibody preferentially immunostains SPARC in fibroblasts and wherein the second anti-SPARC antibody recognizes an immunodominant SPARC epitope recognized by polyclonal antibody AF941(d) determining whether the first anti-SPARC antibody immunostains any component of the tumor;

    (e) determining whether the second anti-SPARC antibody immunostains any component of the tumor; and

    (f) treating the animal by(i) administering the chemotherapeutic regimen if the tumor cells of the pancreatic adenocarcinoma are immunostained with the second anti-SPARC antibody, but not the first anti-SPARC antibody and the immunostaining by the first anti-SPARC antibody of any other component of the tumor has an intensity of 2+ or less;

    (ii) not administering the chemotherapeutic regimen if first anti-SPARC antibody immunostains the tumor cells or immunostains any other component of the tumor with an intensity of 3+; and

    (iii) not administering the chemotherapeutic regimen if second anti-SPARC antibody does not stain the tumor cells.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×